The degradation and clearance of Poly(N-hydroxypropyl-l-glutamine)-DTPA-Gd as a blood pool MRI contrast agent

Biomaterials

Volumn 33, Issue 21, 2012, Pages 5376-5383

  Zhang, Guodong ^a   Zhang, Rui ^a   Melancon, Marites P ^a   Wong, Kelvin ^b   You, Jian ^a   Huang, Qian ^a   Bankson, James ^a   Liang, Dong ^c   Li, Chun ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^c TEXAS SOUTHERN UNIVERSITY   (United States)

Author keywords

Biodegradable; Blood pool imaging; Magnetic resonance imaging; Polymeric gadolinium chelates

Indexed keywords

AMIDE BOND; BIODEGRADABLE; BLOOD POOL; CIRCULATION TIME; CURRENT IMAGING; ENZYMATIC DEGRADATION; ESTER BONDS; GLIOBLASTOMAS; IN-VITRO; IN-VIVO; INTRAVENOUS INJECTIONS; MOUSE BRAIN; MOUSE PLASMA; MRI CONTRAST AGENTS; NONIONIC; PHOTON EMISSIONS; POLYMER BACKBONES; POLYMERIC GADOLINIUM CHELATES; RELAXIVITY; SIDE-CHAINS; TUMOR PERIPHERY;

AMIDES; AMINO ACIDS; BIODEGRADABLE POLYMERS; BIODEGRADATION; BIOSYNTHESIS; CHELATION; DEGRADATION; MAGNETIC RESONANCE IMAGING; MAMMALS; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY;

GADOLINIUM;

AMIDE; CONTRAST MEDIUM; GADOLINIUM; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE DERIVATIVE; INDIUM 111; POLYHYDROXYPROPYLGLUTAMINE GADOLINIUM PENTETATE; POLYMER; PROTEIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BIODEGRADABILITY; BLOOD POOL SCINTISCANNING; BRAIN ANGIOGRAPHY; CHELATION; CHEMICAL BOND; CONTROLLED STUDY; DEGRADATION; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; ISOTOPE LABELING; KIDNEY CLEARANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SYNTHESIS;

ANIMALS; BRAIN; CHROMATOGRAPHY, THIN LAYER; CONTRAST MEDIA; COORDINATION COMPLEXES; FEMALE; GADOLINIUM DTPA; GATED BLOOD-POOL IMAGING; INDIUM RADIOISOTOPES; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED BALB C; PROTEINS; RATS; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

MUS; RATTUS;

EID: 84860916874     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.03.081     Document Type: Article

References (16)

1. Bogdanov A.A., Weissleder R., Frank H.W., Bogdanova A.V., Nossif N., Schaffer B.K., et al. A new macromolecule as a contrast agent for MR angiography: preparation, properties, and animal studies. Radiology 1993, 187:701-706.
2. Kobayashi H., Kawamoto S., Jo S.K., Bryant H.L., Brechbiel M.W., Star R.A. Macromolecular MRI contrast agents with small dendrimers: pharmacokinetic differences between sizes and cores. Bioconjug Chem 2003, 14:388-394.
3. Ladd D.L., Hollister R., Peng X., Wei D., Wu G., Delecki D., et al. Polymeric gadolinium chelate magnetic resonance imaging contrast agents: design, synthesis, and properties. Bioconjug Chem 1999, 10:361-370.
4. Lu Z.R., Wang X., Parker D.L., Goodrich K.C., Buswell H.R. Poly(L-glutamic acid) Gd(III)-DOTA conjugate with a degradable spacer for magnetic resonance imaging. Bioconjug Chem 2003, 14:715-719.
5. Villaraza A.J.L., Bumb A., Brechbiel M.W. Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics. Chem Rev 2010, 110:2921-2959.
6. Tian M., Wen X., Jackson E.F., Ng C., Uthamanthil R., Liang D., et al. Pharmacokinetics and magnetic resonance imaging of biodegradable macromolecular blood-pool contrast agent PG-Gd in non-human primates: a pilot study. Contrast Media Mol Imaging 2011, 6:289-297.
7. Sieber M.A., Lengsfeld P., Frenzel T., Golfier S., Schmitt-Willich H., Siegmund F., et al. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol 2008, 18:2164-2173.
8. Puttagunta N.R., Gibby W.A., Smith G.T. Human in vivo comparative study of zinc and copper transmetallation after administration of magnetic resonance imaging contrast agents. Invest Radiol 1996, 31:739-742.
9. Jackson E.F., Esparza-Coss E., Wen X., Ng C.S., Daniel S.L., Price R.E., et al. Magnetic resonance imaging of therapy-induced necrosis using gadolinium-chelated polyglutamic acids. Int J Radiat Oncol Biol Phys 2007, 68:830-838.
10. Wen X., Jackson E.F., Price R.E., Kim E.E., Wu Q., Wallace S., et al. Synthesis and characterization of poly(L-glutamic acid) gadolinium chelate: a new biodegradable MRI contrast agent. Bioconjug Chem 2004, 15:1408-1415.
11. Aragon C.L., Read M.R., Gaynor J.S., Barnhart M.D., Wilson D., Papich M.G. Pharmacokinetics of an immediate and extended release oral morphine formulation utilizing the spheroidal oral drug absorption system in dogs. J Vet Pharmacol Ther 2009, 32:129-136.
12. Li X.L., Adams N.W., Bennett D.B., Feijen J., Kim S.W. Synthesis of poly(hydroxypropylglutamine-prazosin carbamate) and release studies. Pharm Res 1991, 8:527-530.
13. Zhang G., Zhang R., Wen X., Li L., Li C. Micelles based on biodegradable poly(L-glutamic acid)-b-polylactide with paramagnetic Gd ions chelated to the shell layer as a potential nanoscale MRI-visible delivery system. Biomacromolecules 2008, 9:36-42.
14. Wang W., McMurray J.S., Wu Q., Campbell M.L., Li C. Convenient solid-phase synthesis of diethylenetriaminepenta-acetic acid (DTPA)- conjugated cyclic RGD peptide analogues. Cancer Biother Radiopharm 2005, 20:547-556.
15. Pan H., Kopeckova P., Liu J., Wang D., Miller S.C., Kopecek J. Stability in plasmas of various species of HPMA copolymer-PGE(1) conjugates. Pharm Res 2007, 24:2270-2280.
16. Weinmann H.J., Brasch R.C., Press W.R., Wesbey G.E. Characteristics of gadolinium-DTPA complex - a potential NMR contrast agent. Am J Roentgenol 1984, 142:619-624.